NEW YORK – OncoCyte said today that it has entered into a definitive agreement to acquire Razor Genomics, which developed and markets a prognostic test to assess risk in early-stage lung cancer patients after surgery.
NEW YORK – OncoCyte said today that it has entered into a definitive agreement to acquire Razor Genomics, which developed and markets a prognostic test to assess risk in early-stage lung cancer patients after surgery.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
Privacy Policy. Terms & Conditions. Copyright © 2019 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.